EA
Exome Asset Management LLC
13F filer · CIK 0002011932Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$162MU.S. long equity reported on 13F
Positions5215 new · 8 closed
Net flow last quarter-$35.6MBuys minus sells
Top 10 positions weight44.6%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202652 positions | |||||
| $10.1M | 6.25% | 0.05% | -18.4% | Q1 2024 | |
| $9.11M | 5.62% | 0.10% | -40.2% | Q2 2025 | |
| $9.06M | 5.59% | 0.11% | Not reported | Q4 2023 | |
| $8.15M | 5.03% | 0.12% | -24.4% | Q1 2025 | |
| $6.99M | 4.31% | 0.05% | -19.9% | Q4 2024 | |
| $6.59M | 4.06% | 0.00% | -21.7% | Q4 2023 | |
| $6.25M | 3.85% | 0.06% | New | Q2 2026 | |
| $5.75M | 3.55% | Not reported | -26.8% | Q3 2025 | |
| $5.12M | 3.16% | 0.05% | -42.1% | Q4 2023 | |
| $5.09M | 3.14% | 0.14% | -54.5% | Q1 2024 | |
| $4.17M | 2.57% | 0.14% | -15.4% | Q2 2025 | |
| $4M | 2.46% | 0.00% | -25.3% | Q4 2025 | |
| $3.93M | 2.43% | 0.08% | -33.4% | Q2 2025 | |
| $3.75M | 2.31% | 0.01% | -26.0% | Q4 2023 | |
| $3.73M | 2.30% | 0.12% | Not reported | Q3 2025 | |
| $3.58M | 2.21% | 0.05% | -20.6% | Q4 2023 | |
| $3.42M | 2.11% | 0.21% | +29.6% | Q1 2026 | |
| $3.32M | 2.05% | 0.16% | -23.6% | Q1 2026 | |
| $3.24M | 2.00% | 0.23% | -22.7% | Q4 2023 | |
| $3.21M | 1.98% | 0.04% | -27.1% | Q1 2026 | |
| $3.13M | 1.93% | 0.04% | -14.4% | Q2 2025 | |
| $2.93M | 1.81% | 0.01% | -23.3% | Q3 2025 | |
| $2.78M | 1.71% | 0.03% | -4.9% | Q3 2024 | |
| $2.63M | 1.62% | 0.02% | -29.5% | Q1 2024 | |
| $2.62M | 1.61% | 0.12% | -43.6% | Q1 2024 | |
| $2.3M | 1.42% | 0.46% | -16.6% | Q1 2026 | |
| $2.25M | 1.39% | Not reported | Not reported | Q1 2025 | |
| $2.06M | 1.27% | 0.00% | Not reported | Q4 2024 | |
| $2.05M | 1.27% | 0.82% | -33.7% | Q1 2024 | |
| $1.99M | 1.23% | 0.02% | Not reported | Q4 2023 | |
| $1.95M | 1.20% | 0.00% | -22.8% | Q4 2023 | |
| $1.87M | 1.15% | 0.04% | New | Q2 2026 | |
| $1.78M | 1.10% | 0.08% | Not reported | Q1 2024 | |
| $1.77M | 1.09% | 0.87% | New | Q2 2026 | |
| $1.75M | 1.08% | 0.01% | Not reported | Q2 2024 | |
| $1.73M | 1.07% | 0.99% | -21.0% | Q1 2024 | |
| $1.73M | 1.06% | 0.21% | -11.8% | Q3 2025 | |
| $1.64M | 1.01% | 0.47% | -32.6% | Q2 2025 | |
| $1.56M | 0.97% | 0.11% | Not reported | Q4 2024 | |
| $1.49M | 0.92% | 0.27% | New | Q2 2026 | |
| $1.48M | 0.91% | 0.01% | -48.0% | Q4 2023 | |
| $1.39M | 0.86% | 0.03% | New | Q2 2026 | |
| $1.37M | 0.84% | 0.01% | -72.8% | Q4 2023 | |
| $1.33M | 0.82% | 0.08% | -35.0% | Q1 2026 | |
| $1.13M | 0.69% | 0.22% | Not reported | Q1 2024 | |
| $1.12M | 0.69% | 0.04% | Not reported | Q4 2023 | |
| $889K | 0.55% | 0.02% | -82.9% | Q3 2024 | |
| $799K | 0.49% | 0.10% | Not reported | Q4 2023 | |
| $710K | 0.44% | 0.13% | New | Q2 2026 | |
| $605K | 0.37% | 0.15% | New | Q2 2026 | |
| Q1 2026Reported May 15, 202645 positions | |||||
| $14.6M | 7.58% | 0.16% | -21.8% | Q2 2025 | |
| $10.7M | 5.54% | 0.16% | -8.9% | Q1 2025 | |
| $8.63M | 4.46% | 0.36% | -1.0% | Q1 2024 | |
| $8.26M | 4.27% | 0.07% | -5.5% | Q4 2024 | |
| $7.64M | 3.95% | 0.06% | -15.7% | Q1 2024 | |
| $6.84M | 3.54% | 0.08% | -16.9% | Q4 2023 | |
| $6.45M | 3.34% | 0.00% | -10.7% | Q4 2023 | |
| $6.15M | 3.18% | Not reported | -4.5% | Q3 2025 | |
| $5.01M | 2.59% | 0.03% | -16.4% | Q4 2023 | |
| $4.63M | 2.39% | 0.18% | -7.6% | Q2 2025 | |
| $4.36M | 2.25% | 0.01% | Not reported | Q4 2023 | |
| $4.3M | 2.22% | 0.01% | -14.6% | Q4 2025 | |
| $4.23M | 2.19% | 0.21% | -8.7% | Q1 2024 | |
| $4.18M | 2.16% | 0.02% | -8.2% | Q3 2025 | |
| $4.01M | 2.08% | 0.41% | Not reported | Q4 2023 | |
| $3.73M | 1.93% | 0.01% | Not reported | Q4 2023 | |
| $3.53M | 1.83% | 0.06% | Not reported | Q4 2023 | |
| $3.48M | 1.80% | 0.00% | +120.4% | Q4 2025 | |
| APAPLSApellis Pharmaceuticals, Inc. | $3.44M | 1.78% | 0.07% | -37.1% | Q4 2023 |
| $3.37M | 1.75% | 0.72% | +58.5% | Q2 2025 | |
| $3.27M | 1.69% | 0.12% | -5.8% | Q2 2025 | |
| $3.03M | 1.57% | 0.00% | Not reported | Q4 2024 | |
| $2.97M | 1.54% | 0.05% | New | Q1 2026 | |
| $2.95M | 1.53% | 0.21% | New | Q1 2026 | |
| $2.93M | 1.52% | 0.00% | Not reported | Q4 2023 | |
| $2.89M | 1.49% | 1.24% | -30.5% | Q1 2024 | |
| $2.87M | 1.48% | 0.03% | -8.1% | Q1 2024 | |
| $2.81M | 1.46% | 0.56% | New | Q1 2026 | |
| $2.77M | 1.43% | 0.15% | Not reported | Q3 2024 | |
| $2.64M | 1.37% | 0.18% | New | Q1 2026 | |
| $2.45M | 1.27% | 0.31% | -30.0% | Q3 2025 | |
| $2.38M | 1.23% | 0.65% | Not reported | Q3 2025 | |
| $2.25M | 1.16% | 0.04% | -33.7% | Q3 2024 | |
| $2.2M | 1.14% | 1.32% | +67.8% | Q1 2024 | |
| $2.07M | 1.07% | 0.02% | -30.0% | Q4 2023 | |
| STSLNOSoleno Therapeutics Inc | $2.06M | 1.07% | 0.12% | Not reported | Q4 2024 |
| $1.73M | 0.89% | 0.05% | -49.8% | Q2 2025 | |
| $1.58M | 0.82% | 0.13% | New | Q1 2026 | |
| $1.42M | 0.73% | 0.22% | +15.5% | Q1 2024 | |
| $1.22M | 0.63% | 0.25% | New | Q1 2026 | |
| $1.22M | 0.63% | 3.20% | -30.0% | Q4 2025 | |
| $1.05M | 0.54% | 0.36% | -20.9% | Q4 2025 | |
| $744K | 0.38% | 0.04% | Not reported | Q4 2023 | |
| $486K | 0.25% | 0.81% | New | Q1 2026 | |
| $340K | 0.18% | 0.04% | Not reported | Q4 2024 | |
| Q4 2025Reported Feb 13, 202653 positions | |||||
| $17.1M | 8.19% | 0.23% | -43.0% | Q2 2025 | |
| $10.9M | 5.19% | 0.19% | -31.1% | Q1 2025 | |
| $10M | 4.79% | 0.08% | Not reported | Q1 2024 | |
| $9.22M | 4.41% | 0.07% | -11.1% | Q4 2024 | |
| $8.44M | 4.03% | 0.00% | Not reported | Q4 2023 | |
| $7.93M | 3.79% | 0.10% | -12.4% | Q4 2023 | |
| $7.17M | 3.43% | 0.22% | Not reported | Q2 2024 | |
| $6.3M | 3.01% | 0.19% | -20.3% | Q2 2025 | |
| $6.17M | 2.95% | 0.04% | -39.4% | Q4 2023 | |
| $6.03M | 2.88% | 0.01% | New | Q4 2025 | |
| $5.26M | 2.52% | Not reported | Not reported | Q1 2025 | |
| $4.5M | 2.15% | 0.04% | New | Q4 2025 | |
| $4.27M | 2.04% | 0.01% | Not reported | Q4 2023 | |
| $4.03M | 1.93% | 0.08% | Not reported | Q3 2025 | |
| $3.84M | 1.84% | Not reported | +121.6% | Q2 2025 | |
| $3.74M | 1.79% | 0.02% | +15.7% | Q3 2025 | |
| $3.73M | 1.78% | 0.23% | Not reported | Q1 2024 | |
| $3.71M | 1.77% | 0.12% | -23.8% | Q2 2024 | |
| $3.6M | 1.72% | 0.00% | Not reported | Q4 2023 | |
| $3.55M | 1.70% | 0.05% | +16.0% | Q3 2024 | |
| $3.42M | 1.64% | 0.37% | Not reported | Q1 2024 | |
| $3.42M | 1.64% | 0.07% | New | Q4 2025 | |
| APAPLSApellis Pharmaceuticals, Inc. | $3.41M | 1.63% | 0.11% | Not reported | Q4 2023 |
| $3.4M | 1.63% | 0.10% | -43.3% | Q4 2023 | |
| $3.33M | 1.59% | 0.01% | Not reported | Q4 2023 | |
| $3.3M | 1.58% | 0.04% | -52.4% | Q1 2024 | |
| $3.17M | 1.52% | 0.44% | Not reported | Q3 2025 | |
| $3.14M | 1.50% | 0.10% | -3.3% | Q2 2025 | |
| $3.1M | 1.48% | 0.52% | Not reported | Q2 2025 | |
| $2.85M | 1.36% | Not reported | -0.2% | Q3 2025 | |
| $2.8M | 1.34% | 0.02% | Not reported | Q4 2023 | |
| $2.67M | 1.28% | 0.13% | Not reported | Q2 2025 | |
| $2.66M | 1.27% | 0.15% | New | Q4 2025 | |
| $2.48M | 1.19% | 0.09% | -42.3% | Q3 2024 | |
| $2.34M | 1.12% | 4.71% | New | Q4 2025 | |
| $2.29M | 1.10% | 0.04% | New | Q4 2025 | |
| $2.26M | 1.08% | 0.04% | +47.1% | Q2 2025 | |
| $2.19M | 1.04% | 0.40% | New | Q4 2025 | |
| $2.18M | 1.04% | 1.61% | New | Q4 2025 | |
| $2M | 0.96% | 1.79% | Not reported | Q1 2024 | |
| $1.99M | 0.95% | 0.19% | -65.3% | Q1 2024 | |
| $1.93M | 0.92% | 0.00% | New | Q4 2025 | |
| $1.78M | 0.85% | 0.48% | New | Q4 2025 | |
| $1.76M | 0.84% | 0.12% | +24.8% | Q3 2025 | |
| $1.4M | 0.67% | 0.19% | Not reported | Q2 2024 | |
| $1.23M | 0.59% | 0.46% | New | Q4 2025 | |
| $1.21M | 0.58% | 0.00% | New | Q4 2025 | |
| $1.21M | 0.58% | 0.01% | -66.4% | Q2 2025 | |
| $1.14M | 0.54% | 0.79% | -39.3% | Q1 2024 | |
| $1.04M | 0.50% | 0.14% | -6.8% | Q2 2024 | |
| Q3 2025Reported Nov 14, 202552 positions | |||||
| $8.57M | 5.19% | 0.08% | +8.2% | Q4 2024 | |
| $7.83M | 4.74% | 0.12% | +23.0% | Q4 2023 | |
| $6.91M | 4.19% | 0.07% | -14.4% | Q4 2023 | |
| $6.37M | 3.86% | 0.32% | -16.9% | Q1 2025 | |
| $6.13M | 3.71% | 0.08% | Not reported | Q1 2024 | |
| $5.99M | 3.63% | 0.00% | +68.0% | Q4 2023 | |
| $5.44M | 3.30% | 0.54% | Not reported | Q1 2024 | |
| $5.41M | 3.27% | 0.48% | +72.9% | Q2 2025 | |
| $4.54M | 2.75% | 0.24% | +103.5% | Q2 2025 | |
| $4.27M | 2.59% | Not reported | Not reported | Q1 2025 | |
| $4.05M | 2.46% | 0.18% | Not reported | Q2 2024 | |
| 8ETNB89bio, Inc. | $4.02M | 2.44% | 0.18% | +17.2% | Q3 2024 |
| ATAPGEApogee Therapeutics, Inc. | $3.75M | 2.27% | 0.16% | New | Q3 2025 |
| $3.75M | 2.27% | 0.18% | +2.4% | Q4 2023 | |
| $3.68M | 2.23% | 0.02% | -33.0% | Q2 2025 | |
| $3.6M | 2.18% | 0.08% | Not reported | Q1 2024 | |
| $3.29M | 1.99% | 0.00% | New | Q3 2025 | |
| STSLNOSoleno Therapeutics Inc | $3.27M | 1.98% | 0.09% | +16.3% | Q4 2024 |
| $3M | 1.82% | 0.01% | Not reported | Q4 2023 | |
| $2.91M | 1.76% | 1.83% | -17.1% | Q1 2024 | |
| $2.84M | 1.72% | 0.00% | Not reported | Q4 2023 | |
| $2.81M | 1.70% | 0.16% | +39.3% | Q3 2024 | |
| $2.79M | 1.69% | 0.02% | New | Q3 2025 | |
| ATAKROAkero Therapeutics, Inc. | $2.78M | 1.68% | 0.07% | Not reported | Q3 2024 |
| $2.56M | 1.55% | 0.09% | New | Q3 2025 | |
| $2.55M | 1.54% | 0.29% | -45.6% | Q4 2023 | |
| $2.38M | 1.44% | 0.45% | New | Q3 2025 | |
| $2.28M | 1.38% | 0.02% | Not reported | Q4 2023 | |
| $2.21M | 1.34% | 0.05% | Not reported | Q3 2024 | |
| $2.14M | 1.30% | 0.11% | +359.7% | Q2 2025 | |
| CPCNTACentessa Pharmaceuticals PLC | $2.13M | 1.29% | 0.07% | -47.3% | Q1 2024 |
| $1.91M | 1.16% | 0.13% | Not reported | Q2 2025 | |
| $1.88M | 1.14% | 0.00% | New | Q3 2025 | |
| $1.81M | 1.10% | 0.14% | -61.8% | Q4 2024 | |
| $1.78M | 1.08% | 0.03% | Not reported | Q2 2025 | |
| $1.63M | 0.98% | Not reported | -21.2% | Q2 2025 | |
| $1.45M | 0.88% | 0.12% | New | Q3 2025 | |
| $1.42M | 0.86% | 0.07% | New | Q3 2025 | |
| $1.38M | 0.84% | 0.06% | New | Q3 2025 | |
| $1.29M | 0.78% | 0.04% | New | Q3 2025 | |
| $1.28M | 0.77% | 0.34% | Not reported | Q4 2023 | |
| $1.27M | 0.77% | 0.56% | New | Q3 2025 | |
| $1.19M | 0.72% | 0.20% | -58.9% | Q2 2024 | |
| $1.17M | 0.71% | Not reported | New | Q3 2025 | |
| $977K | 0.59% | 0.10% | New | Q3 2025 | |
| $917K | 0.56% | 0.12% | -16.9% | Q1 2025 | |
| $909K | 0.55% | 0.18% | -77.8% | Q2 2024 | |
| $537K | 0.33% | 0.05% | Not reported | Q4 2023 | |
| $343K | 0.21% | 0.04% | Not reported | Q4 2024 | |
| $308K | 0.19% | 0.09% | -81.5% | Q4 2024 | |
Premium opens every quarter this fund has filed